In news- Recently, US Pharma Giant Pfizer has received USFDA emergency use authorization for its Covid-19 antiviral treatment Paxlovid.
- It is an antiviral Covid-19 treatment candidate, PF-07321332, which is administered in combination with low dose HIV medicine ritonavir.
- It showed a reduced risk of hospitalisation or death by 89 per cent, within three days of symptom onset; and 88 per cent, within five days of symptom onset, as compared to the placebo group.
- Paxlovid can be used to treat adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease.
- Pfizer announced a deal with the United Nations backed public health organization Medicines Patent Pool (MPP).
- Under the deal, it signed a voluntary license agreement for Covid-19 oral antiviral treatment candidate Paxlovid.
- The agreement will facilitate the production and distribution of Paxlovid by granting sub-licenses to qualified generic medicine manufacturers.
- The drug, Paxlovid, is a faster way to treat early COVID-19 infections, though initial supplies will be extremely limited.
- All of the previously authorized drugs against the disease require an IV or an injection.